- NEGATIVE
Quarterly Revenue Alpa Laboratories Jun-2026 Quarterly Revenue is Rs 30 Cr which is growth of -4.2% YoY.
- NEGATIVE
Quarterly Net Profit Alpa Laboratories Jun-2026 Quarterly Net Profit is Rs 1 Cr which is growth of -91.2% YoY.
NSE: ALPA | BSE: 532878
Alpa Laboratories Live Share Price Today, Share Analysis and Chart
aboutAlpa Laboratories Ltd. is a pharmaceutical company involved in the research, development, and manufacturing of high-quality formulations across diverse therapeutic segments. Established in 1988 and headquartered in Indore, India, the company produces... Read More
50.38-2.24(-4.26%)
18,202
NSE+BSE Volume
NSE 30 Oct, 2026 3:31 PM (IST)
Slowing Down StockThese stocks have medium financials and valuations, but weak momentum indicating decreasing investor interestView SimilarEmbed DVM
Please subscribe to view forecaster data
Alpa Laboratories Stock Price Analysis
Day Price Range-4.3% 1 Day return | 50.4 (LTP) 5051.6 LowHigh |
|---|---|
Week Price Range2.2% 1 Week return | 50.4 (LTP) 46.853.3 LowHigh |
Month Price Range-15.3% 1 Month return | 50.4 (LTP) 46.860.5 LowHigh |
52 Week Price Range-45.0% 1 Year return | 50.4 (LTP) 46.192.5 LowHigh |
Competitors/Peers
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Alpa Laboratories quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.8 | 31.2 | 29.9 | 29.3 | 31.1 | 42.4 | 35 | 31.9 | 26.6 | 27.6 | 30.8 | 35.4 | 29.9 | ||
Operating Exp. | 27.9 | 27.8 | 27.5 | 28.5 | 18.7 | 39.5 | 25.4 | 21.7 | 20.9 | 20.1 | 24.9 | 29.1 | 26.6 | |
Operating Profit | -4 | 3.6 | 2.1 | -2.9 | 0.4 | -0.4 | 0.7 | 3.3 | 0.5 | 3.5 | 2.5 | 3.3 | -1.2 | |
Operating Profit Margin % | -16.53% | 11.50% | 7.20% | -11.19% | 2.22% | -0.92% | 2.84% | 13.12% | 2.53% | 14.90% | 9.01% | 10.23% | -4.52% | |
Depr. | 0.7 | 0.2 | 0.7 | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.7 | 0.5 | 0.3 | |
Interest | 0.1 | 0.2 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0 | 0 | 0 | |
Profit Before Tax | 1 | 3 | 1.7 | 0.1 | 11.8 | 2.3 | 8.9 | 9.6 | 5.1 | 6.7 | 5.3 | 5.7 | 3 | |
Tax | 1.7 | -0.2 | 4.2 | 2 | 3.1 | 0.8 | ||||||||
Net Profit | 1 | 1.4 | 1.9 | 0.1 | 11.8 | -2 | 8.9 | 7.6 | 5.1 | 3.6 | 4.5 | 5.7 | 3 | |
EPS Adj. latest | 0.5 | 0.6 | 0.9 | 0.1 | 5.6 | -0.9 | 4.2 | 3.6 | 2.4 | 1.7 | 2.2 | 2.7 | 1.4 | |
Net profit TTM | 4.4 | 15.1 | 11.8 | 18.8 | 26.4 | 19.7 | 25.2 | 20.8 | 18.9 | 16.8 | 17.9 | 18.5 | 13 | |
Basic EPS TTM | 2.1 | 7.2 | 5.6 | 9 | 12.5 | 9.4 | 12 | 9.9 | 9 | 8 | 8.5 | 8.8 | 6.2 | |
Results PDF | ||||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Alpa Laboratories Technical Analysis
Alpa Laboratories EMA & SMA
Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
| 5 Day | 51.3 |
|---|---|
| 10 Day | 52.1 |
| 12 Day | 52.4 |
| 20 Day | 53.9 |
| 26 Day | 54.9 |
|---|---|
| 50 Day | 57.9 |
| 100 Day | 61.5 |
| 200 Day | 67.1 |
Alpa Laboratories Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 202666.6%
Week70.8%
Month66.2%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Alpa Laboratories Resistance and Support
50.68
Pivot
| First Resistance | 51.4 |
|---|---|
| Second Resistance | 52.3 |
| Third Resistance | 53 |
| First Support | 49.7 |
|---|---|
| Second Support | 49.0 |
| Third Support | 48.1 |
| Day RSI | 34.6 |
|---|---|
| Day MACD | -2.5 |
| Day MFI | 24.4 |
| Day MACD Signal Line | -2.4 |
Alpa Laboratories Beta
| 1 Month | 0.6 |
|---|---|
| 1 Year | 1.0 |
| 3 Month | 0.5 |
|---|---|
| 3 Year | 1.1 |
Alpa Laboratories Price Change Analysis
↓-15.3%
Over 1 Month
LowHigh
46.960.5
↓-24.6%
Over 3 Months
LowHigh
46.972.5
↓-23.9%
Over 6 Months
LowHigh
46.978.9
↓-45.0%
Over 1 Year
LowHigh
46.192.5
Alpa Laboratories Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| PRADEEP KUMAR JAIN | Bulk | Sell | 30 Sep 2024 | 138.81 | 125,141 | NSE |
| MUDUPULAVEMULA SURENDRANADHA REDDY | Bulk | Sell | 30 Sep 2024 | 139.35 | 169,278 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 30 Sep 2024 | 138.79 | 183,809 | NSE |
| AAKRAYA RESEARCH LLP | Bulk | Sell | 30 Sep 2024 | 140.23 | 246,714 | NSE |
| HRTI PRIVATE LIMITED | Bulk | Sell | 30 Sep 2024 | 139.81 | 138,942 | NSE |
| MICROCURVES TRADING PRIVATE LIMITED | Bulk | Sell | 30 Sep 2024 | 139.56 | 122,111 | NSE |
| QE SECURITIES LLP | Bulk | Sell | 30 Sep 2024 | 139.75 | 200,761 | NSE |
| HRTI PRIVATE LIMITED | Bulk | Purchase | 30 Sep 2024 | 139.42 | 155,746 | NSE |
| QE SECURITIES LLP | Bulk | Purchase | 30 Sep 2024 | 139.76 | 203,805 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Purchase | 30 Sep 2024 | 138.69 | 183,809 | NSE |
Alpa Laboratories Corporate Actions
Alpa Laboratories Board Meetings
Alpa Laboratories past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
114 Aug 2026 | Quarterly Results | - |
229 May 2026 | Audited Results | - |
311 Feb 2026 | Quarterly Results | - |
414 Nov 2025 | Quarterly Results | - |
513 Aug 2025 | Quarterly Results & A.G.M. | - |
Alpa Laboratories Corporate Filings
Alpa Laboratories BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 14 Oct 2026 | Alpa Laboratories Ltd - 532878 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Alpa Laboratories Limited hereby submit to the Exchange the Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Prticipants) Regulations, 2018. | |
| 12 Oct 2026 | Alpa Laboratories Ltd - 532878 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report | Alpa Laboratories Limited has submitted the Exchange a copy of Scrutinizer''s Report of its 38th Annual General Meeting. | |
| 30 Sep 2026 | Alpa Laboratories Ltd - 532878 - Shareholder Meeting / Postal Ballot-Outcome of AGM | Summary of Proceedings of 38th Annual General Meeting of the Company held on Wednesday, 30th September 2026 pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015. | |
| 29 Sep 2026 | Alpa Laboratories Ltd - 532878 - Closure of Trading Window | Intimation of closure of trading window. | |
| 17 Sep 2026 | Alpa Laboratories Ltd - 532878 - Appointment of Company Secretary and Compliance Officer | Appointment of Ms. Diksha Jaswani, as a company secretary cum compliance officer of the company w.e.f September 17,2026. |
Alpa Laboratories Documents
Alpa Laboratories Annual Reports
Alpa Laboratories financials, including annual results, balance sheets, and cash flow statements.
Alpa Laboratories Credit Ratings
Alpa Laboratories credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 22 Mar 2026 | care ratings | Alpa Infrastructure Limited | Link | |
| 05 Mar 2026 | icra ratings | ALPA INFRASTRUCTURE LIMITED | Ratings assigned | Link |
| 28 Aug 2025 | crisil ratings | Alpa Laboratories Limited | Alpa Laboratories Limited:Issuer not cooperating, based on best-available information; Ratings continues to be \u2018Crisil B/Stable/Crisil A4 Issuer not cooperating\u2019 | Link |
| 20 Feb 2025 | care ratings | Alpa Infrastructure Limited | Link | |
| 28 Jun 2024 | crisil ratings | Alpa Laboratories Limited | Alpa Laboratories Limited:Issuer not cooperating, based on best-available information; Ratings continues to be \u2018CRISIL B/Stable/CRISIL A4 Issuer not cooperating' | Link |
Alpa Laboratories - Company Profile
Alpa Laboratories Management Structure
Alpa Laboratories management structure with salaries, total experience, and qualifications.
Alpa Laboratories Board of Directors
Alpa Laboratories Board of directors with salaries, total experience, and qualifications.
Website: www.alpalabs.in
About the company - Business Profile
Alpa Laboratories Ltd. is a pharmaceutical company involved in the research, development, and manufacturing of high-quality formulations across diverse therapeutic segments. Established in 1988 and headquartered in Indore, India, the company produces a wide range of products including ethical, generic, and over-the-counter (OTC) medicines. Its offerings encompass various dosage forms such as injections, tablets, capsules, ointments, and powders, catering to both domestic and international markets.
Key Points
Key Facts
- Founded Year: 1988
- Headquarters: Indore, Madhya Pradesh, India
- Stock Listing: National Stock Exchange (NSE: ALPA) and Bombay Stock Exchange (BSE: 532878)
- Primary Business: Pharmaceutical formulations and branded generics
Operations and Resources
- Facilities: The company operates integrated manufacturing facilities located at Pigdamber, Indore. These units are designed to meet international regulatory standards and house production lines for multiple dosage forms.
- Notable Assets: As of March 31, 2025, the company reported consolidated property, plant, and equipment valued at approximately Rs. 3,000.44 lacs.
Business Model and Market Significance
- Model: Alpa Laboratories operates on a model of vertical integration in pharmaceutical formulation manufacturing. It focuses on branded generics to provide affordable treatment options.
- Market Position: The company serves both the domestic Indian market and various international geographies, positioning itself as a growing provider of affordable healthcare solutions.
Revenue and Financial Performance (FY 2024-25)
- Total Income: Rs. 13,575.71 lacs (9.82% growth from Rs. 12,361.28 lacs in FY 2023-24).
- Revenue from Operations: Rs. 11,245.51 lacs (Consolidated).
- EBITDA: Rs. 2,830.99 lacs, marking a 22.99% increase year-on-year.
- Profit After Tax (PAT): Rs. 1,982.90 lacs, reflecting a 17.62% growth over the previous year.
- Geographical Breakdown: The company generates revenue from both domestic sales and exports, though specific percentage splits for the full year are not explicitly detailed in the summary financial tables.
Key Products and Technology
- Product Categories: Therapeutic segments covered include anti-infectives, analgesics, anti-inflammatory drugs, and various life-saving medicines.
- Dosage Forms: Sterile and non-sterile formulations including liquid and dry powder injections, tablets (coated and uncoated), capsules, and topical ointments.
- Technological Advancement: Operations focus on maintaining compliance with stringent quality standards and international regulatory norms through technology upgrades in manufacturing and research.
Workforce and Human Capital
- Employee Count: 453 permanent employees as of March 31, 2025.
- Hiring Trends: The workforce grew by approximately 10.48% from 410 employees in the previous year, driven by expanding scales of operation and new market penetration.
- Retention Initiatives: Focus on training and development programs, participative management, and employee well-being initiatives such as long-term service awards and medical insurance.
Strategic Initiatives and Outlook
- Growth Strategy: The company is focusing on expanding its product pipeline, particularly in branded generics, and increasing its penetration in new international markets.
- Investment: Continued investment in capacity expansion, technological upgrades, and R&D-driven innovation.
- Financial Stability: Management maintains a focus on prudent financial management and a strong balance sheet to support long-term sustainable growth and potential strategic partnerships.
References